The recent FDA warning addressing the use of power morcellation has sparked great debate. The FDA estimates 1 in 350 women undergoing hysterectomy or myomectomy for the treatment of fibroids is found to have an unsuspected uterine sarcoma.  This is concerning for a tertiary referral centre performing a large number of minimally invasive procedures for management of fibroids.  We undertook a retrospective analysis of all hysterectomies and myomectomies over a 16 year period to evaluate the incidence of unexpected uterine neoplasms. Patient demographics, preoperative workup and operative indication were examined. These results as well as a review of current literature regarding the investigation and management of uterine fibroids will be discussed.